Mindstate Design Labs

About

Mindstate Design Labs is a clinical-stage biotechnology company based in San Francisco, founded in 2021 by Dillan DiNardo and Tom Ray. The company focuses on mental health innovation by integrating AI, neuroengineering, and psychedelic-inspired therapeutics. Their AI-driven platform, Osmanthus, analyzes large datasets to identify patterns in neurotransmitter receptor activity associated with various emotional and cognitive states. Mindstate is developing a drug pipeline that includes MSD-001, a non-hallucinogenic compound currently in human trials aimed at enhancing emotional and cognitive flexibility. They also work on psychedelic primer compounds and non-psychedelic probes that modulate conscious states without inducing hallucinations. The company targets mental health conditions such as depression, PTSD, and anxiety, aligning with the growing interest in psychedelic-inspired medicines.